We’ve been working to develop synthetic vaccines that educate our immune systems to recognize and attack cancer cells, in collaboration with the Malaghan Institute of Medical Research, Wellington.
Our expertise as carbohydrate specialists positioned us perfectly for this challenge. We’ve been able to detect differences between the carbohydrates present on the cell surface of all normal and diseased tissue, and mimic the carbohydrate-based danger signals that trigger an immune response.
Through this research, the ambition is to develop a synthetic cancer vaccine technology that can activate the patient’s own immune system to provide a targeted immune response to their cancer. In 2019, this was taken a step further when we manufactured GMP material for a first-in-human clinical trial, investigating this adjuvant technology for a melanoma vaccine.